Bisphosphonate-Related Subtrochanteric Femoral Fractures

There is no rationale for withholding bisphosphonate therapy from patients with osteoporosis, although continued use of bisphosphonates beyond a treatment period of 3 to 5 years should be reevaluated annually. In patients who have been on long-term bisphosphonate therapy, physicians should specifically solicit information of unique clinical features and consider imaging, when appropriate.